Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Boserolimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Boserolimab - Merck Sharp & Dohme

Alternative Names: anti-cd27 agonist - Chinook Therapeutics; anti-CD27 antibody- Chinook Therapeutics; MK 5890

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNovion
  • Developer Merck Sharp & Dohme
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD27 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 Jun 2025 Merck Sharp & Dohme withdraws a phase II trial prior to enrollment in Triple-negative-breast-cancer (Combination therapy, Early-stage disease, Newly diagnosed, First-line therapy) in the US Taiwan (IV) (NCT06829199)
  • 28 May 2025 Merck Sharp & Dohme completes a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Spain, South Korea, Poland, Italy, Israel, Hungary (IV) (NCT04165096) (EudraCT2020-001629-29)
  • 17 Feb 2025 Merck Sharp & Dohme plans the phase II MK-5890-003 trial for Triple-negative-breast-cancer (Early-stage disease, Combination therapy, First-line therapy) (IV, Infusion), in March 2025 (NCT06829199), (EudraCT2024-517505-87),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top